孤儿药物指定-话题@MedSci

#孤儿药物指定#

18篇内容 | 683人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1740160, encodeId=7f621e4016003, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定, objectType=article, longId=197998, objectId=2dca19e99888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dca19e99888, replyNumber=0, likeNumber=49, createdTime=2020-09-28, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dca19e99888, moduleTitle=miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dca19e99888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740155, encodeId=b79e1e401557b, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=脑转移性乳腺癌的治疗进展：FDA授予NERLYNX孤儿药物指定, objectType=article, longId=178843, objectId=ea0e1e88433a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea0e1e88433a, replyNumber=0, likeNumber=49, createdTime=2019-09-11, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea0e1e88433a, moduleTitle=脑转移性乳腺癌的治疗进展：FDA授予NERLYNX孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea0e1e88433a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740153, encodeId=01dd1e401533a, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Neuropore宣布其NPT520-34治疗肌萎缩性脊髓侧索硬化症，喜获FDA的孤儿药物指定, objectType=article, longId=177715, objectId=7abe1e771504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7abe1e771504, replyNumber=0, likeNumber=45, createdTime=2020-05-07, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7abe1e771504, moduleTitle=Neuropore宣布其NPT520-34治疗肌萎缩性脊髓侧索硬化症，喜获FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7abe1e771504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740152, encodeId=909b1e4015223, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=中心核肌病反义核酸药物DYN101获得FDA孤儿药物指定, objectType=article, longId=177565, objectId=653d1e756528, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=653d1e756528, replyNumber=0, likeNumber=32, createdTime=2020-07-24, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=653d1e756528, moduleTitle=中心核肌病反义核酸药物DYN101获得FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=653d1e756528)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740154, encodeId=b5191e4015462, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, objectType=article, longId=178782, objectId=c6a71e8782a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6a71e8782a5, replyNumber=0, likeNumber=49, createdTime=2020-03-03, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6a71e8782a5, moduleTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6a71e8782a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740159, encodeId=310e1e4015901, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定, objectType=article, longId=182512, objectId=6d2018251202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d2018251202, replyNumber=0, likeNumber=49, createdTime=2020-07-17, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d2018251202, moduleTitle=Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d2018251202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740156, encodeId=92bc1e40156da, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=骨髓增生异常综合征的治疗：ASTX727已获美国FDA的孤儿药物指定, objectType=article, longId=178844, objectId=61061e884412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61061e884412, replyNumber=0, likeNumber=34, createdTime=2020-04-30, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61061e884412, moduleTitle=骨髓增生异常综合征的治疗：ASTX727已获美国FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61061e884412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740151, encodeId=e7391e40151f6, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Aridis柠檬酸镓吸入剂AR-501治疗囊性纤维化肺部感染，喜获EMA孤儿药物指定, objectType=article, longId=175954, objectId=2cb91e5954e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb91e5954e9, replyNumber=0, likeNumber=31, createdTime=2020-04-20, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb91e5954e9, moduleTitle=Aridis柠檬酸镓吸入剂AR-501治疗囊性纤维化肺部感染，喜获EMA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb91e5954e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740150, encodeId=ca2a1e40150c1, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, objectType=article, longId=175359, objectId=a0671e535994, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0671e535994, replyNumber=0, likeNumber=52, createdTime=2019-12-07, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0671e535994, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0671e535994)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740157, encodeId=38891e4015712, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=美国FDA授予Nomacopan治疗大疱性类天疱疮的孤儿药物指定, objectType=article, longId=179480, objectId=a6c61e94804e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6c61e94804e, replyNumber=0, likeNumber=42, createdTime=2020-06-11, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6c61e94804e, moduleTitle=美国FDA授予Nomacopan治疗大疱性类天疱疮的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6c61e94804e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740149, encodeId=d3a01e401496b, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Autolus双靶头CAR-T疗法AUTO3治疗急性淋巴细胞白血病，获得FDA授予的孤儿药物指定, objectType=article, longId=164953, objectId=996316495364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996316495364, replyNumber=0, likeNumber=48, createdTime=2019-06-10, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996316495364, moduleTitle=Autolus双靶头CAR-T疗法AUTO3治疗急性淋巴细胞白血病，获得FDA授予的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=996316495364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740145, encodeId=b22c1e40145bd, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=FDA授予OCU400孤儿药物指定以治疗NR2E3突变相关的视网膜退行性疾病, objectType=article, longId=160344, objectId=f03316034403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f03316034403, replyNumber=0, likeNumber=37, createdTime=2019-09-23, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f03316034403, moduleTitle=FDA授予OCU400孤儿药物指定以治疗NR2E3突变相关的视网膜退行性疾病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f03316034403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740147, encodeId=43061e401470c, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Espero BioPharma宣布Tecarfarin治疗终末期肾病和心房颤动患者获得FDA孤儿药物指定, objectType=article, longId=162178, objectId=41161621e864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41161621e864, replyNumber=0, likeNumber=43, createdTime=2019-06-10, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41161621e864, moduleTitle=Espero BioPharma宣布Tecarfarin治疗终末期肾病和心房颤动患者获得FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41161621e864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740158, encodeId=fd0f1e4015848, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Glenmark双特异性抗体GBR 1342治疗多发性骨髓瘤，喜获FDA孤儿药物指定, objectType=article, longId=179623, objectId=75b91e96234a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75b91e96234a, replyNumber=0, likeNumber=57, createdTime=2020-03-13, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75b91e96234a, moduleTitle=Glenmark双特异性抗体GBR 1342治疗多发性骨髓瘤，喜获FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75b91e96234a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740146, encodeId=a3221e40146e9, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Mitochon Pharmaceuticals的MP-101治疗亨廷顿舞蹈病获得FDA孤儿药物指定, objectType=article, longId=161780, objectId=3be5161e8072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3be5161e8072, replyNumber=0, likeNumber=46, createdTime=2019-09-04, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3be5161e8072, moduleTitle=Mitochon Pharmaceuticals的MP-101治疗亨廷顿舞蹈病获得FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3be5161e8072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740148, encodeId=17721e401489c, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Viracta的HDAC抑制剂nanatinostat治疗EBV相关癌症，获得美国FDA的孤儿药物指定, objectType=article, longId=164502, objectId=df0c164502be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df0c164502be, replyNumber=0, likeNumber=31, createdTime=2019-07-09, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df0c164502be, moduleTitle=Viracta的HDAC抑制剂nanatinostat治疗EBV相关癌症，获得美国FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df0c164502be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740143, encodeId=e9d81e40143d5, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定, objectType=article, longId=149700, objectId=ed23149e009d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed23149e009d, replyNumber=0, likeNumber=57, createdTime=2018-11-26, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed23149e009d, moduleTitle=Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed23149e009d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1740144, encodeId=a4351e4014434, content=<a href='/topic/show?id=99f2454322e' target=_blank style='color:#2F92EE;'>#孤儿药物指定#</a>, objectTitle=MB-102（CD123 CAR T）获得FDA孤儿药物指定用于治疗浆细胞样树突状细胞肿瘤, objectType=article, longId=156453, objectId=e4e31564538b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4e31564538b, replyNumber=0, likeNumber=50, createdTime=2019-08-22, rootId=0, userName=12498b37m83暂无昵称, userId=1d3d34654584, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4e31564538b, moduleTitle=MB-102（CD123 CAR T）获得FDA孤儿药物指定用于治疗浆细胞样树突状细胞肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4e31564538b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

孤儿药物指定

2020-05-29

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

miR-155抑制剂治疗T细胞淋巴瘤，获得美国FDA的孤儿药物指定

2020-09-28

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

脑转移性乳腺癌的治疗进展：FDA授予NERLYNX孤儿药物指定

2019-09-11

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Neuropore宣布其NPT520-34治疗肌萎缩性脊髓侧索硬化症，喜获FDA的孤儿药物指定

2020-05-07

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

中心核肌病反义核酸药物DYN101获得FDA孤儿药物指定

2020-07-24

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定

2020-03-03

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Autolus的快速解离型CAR-T细胞疗法治疗急性淋巴细胞白血病，获FDA孤儿药物指定

2020-07-17

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

骨髓增生异常综合征的治疗：ASTX727已获美国FDA的孤儿药物指定

2020-04-30

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Aridis柠檬酸镓吸入剂AR-501治疗囊性纤维化肺部感染，喜获EMA孤儿药物指定

2020-04-20

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌，获得FDA的孤儿药物指定

2019-12-07

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

美国FDA授予Nomacopan治疗大疱性类天疱疮的孤儿药物指定

2020-06-11

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Autolus双靶头CAR-T疗法AUTO3治疗急性淋巴细胞白血病，获得FDA授予的孤儿药物指定

2019-06-10

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

FDA授予OCU400孤儿药物指定以治疗NR2E3突变相关的视网膜退行性疾病

2019-09-23

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Espero BioPharma宣布Tecarfarin治疗终末期肾病和心房颤动患者获得FDA孤儿药物指定

2019-06-10

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Glenmark双特异性抗体GBR 1342治疗多发性骨髓瘤，喜获FDA孤儿药物指定

2020-03-13

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Mitochon Pharmaceuticals的MP-101治疗亨廷顿舞蹈病获得FDA孤儿药物指定

2019-09-04

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Viracta的HDAC抑制剂nanatinostat治疗EBV相关癌症，获得美国FDA的孤儿药物指定

2019-07-09

zhouqu_8 (审核中...)

前往app查看评论内容

#孤儿药物指定#

Portola口服Syk/JAK抑制剂Cerdlatinib治疗外周T细胞淋巴瘤获得FDA孤儿药物指定

2018-11-26

12498b37m83暂无昵称 (审核中...)

前往app查看评论内容

#孤儿药物指定#

MB-102（CD123 CAR T）获得FDA孤儿药物指定用于治疗浆细胞样树突状细胞肿瘤

2019-08-22

科室
- - 订阅+
  - 更多科室
工具
服务